Difference between revisions of "Editing test page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Replaced content with "==Carboplatin & Paclitaxel (CP) & Nivolumab {{#subobject:3a6hg7|Regimen=1}}== CP & Nivolumab: '''<u>C</u>'''arboplatin, '''<u>P</u>'''aclitaxel, Nivolumab <div class="tocc...")
Tag: Replaced
 
(196 intermediate revisions by 4 users not shown)
Line 1: Line 1:
−
{{DISPLAYTITLE:<span style="display: none"></span>}}
+
==Carboplatin & Paclitaxel (CP) & Nivolumab {{#subobject:3a6hg7|Regimen=1}}==
−
<!--Hides title of Main Page-->
+
CP & Nivolumab: '''<u>C</u>'''arboplatin, '''<u>P</u>'''aclitaxel, Nivolumab
−
<div style="text-align:center">
+
<div class="toccolours" style="background-color:#eeeeee">
−
<h1>'''HemOnc.org - A Free Hematology/Oncology Reference'''</h1>
+
===Regimen variant #1, 5/175/360 {{#subobject:59hhq7|Variant=1}}===
−
</div>
+
{| class="wikitable sortable" style="width: 100%; text-align:center;"
−
 
+
!style="width: 20%"|Study
−
<span id="BackToTop"></span>
+
!style="width: 20%"|Dates of enrollment
−
<div class="noprint" style="background-color:#FAFAFA; position:fixed; bottom:2%; rightt:0.25%; padding:0; margin:0;">
+
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
[[#BackToTop|Back to Top]]
+
!style="width: 20%"|Comparator
−
</div>
+
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
−
 
 
−
{| border="1"; style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
 
 
|-
 
|-
−
|colspan="4" style="background-color:#505050"|
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844511/ Forde et al. 2022 (CheckMate 816)]
 +
{| class="wikitable" style="margin:auto; color:black; background-color:#d3d3d3"
 +
|[[File:HopeAI.png|link=https://hemonc.org|alt=Alt text|Title=text|frameless|150px|center]]
 
|-
 
|-
−
|colspan="2" style="background-color:#66FF66"|'''[[Tutorial#Regimens|Regimens]]: {{#ask: [[Regimen::+]] |?Regimen |limit=10000|format=sum}}'''
+
|Click to learn more!
−
|colspan="2" style="background-color:#66CCFF"|'''Regimen variants: {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}'''
 
 
|-
 
|-
−
|colspan="4" style="background-color:#505050"|
 
−
|-
 
−
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_desktop Desktop Version]'''
 
−
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile Mobile Version]'''
 
−
|style="background-color:#F0F0F0"|'''[[How to add HemOnc.org to your home screen | Mobile shortcut]]'''
 
−
|style="background-color:#F0F0F0"|'''[[Hematology Oncology Fellowship Programs Directory|Fellowship programs]]'''
 
−
|-
 
−
|colspan="4" background-color:#FFFFE0"|<big>[[Editorial Board]]</big>
 
−
|-
 
−
|style="background-color:#F0F0F0"|[[:Category:Disease index|Disease index]]
 
−
|style="background-color:#F0F0F0"|[[:Category:Drug index|Drug index]]
 
−
|style="background-color:#F0F0F0"|[[:Category:Regimen index|Regimen index]]
 
−
|style="background-color:#F0F0F0"|[[:Category:General reference pages|General reference]]
 
−
|-
 
−
|[[#solidtumors|Solid Tumors]]
 
−
|[[#malignantheme|Malignant Hematology]]
 
−
|[[#otherheme|Other Hematology]]
 
−
|}
 
−
 
−
<div style="text-align:center"><big>'''If this is your first time visiting, please [[Tutorial|go to the tutorial page]] or just start exploring!'''</big></div>
 
−
 
−
==Links to Main Disease Pages==
 
−
<span id="solidtumors"></span>
 
−
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
−
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#00008B"| '''Solid Tumors'''
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Breast Oncology'''
 
−
|-
 
−
|colspan="2" style="background-color:#F0F8FF"|[[Breast cancer]]
 
−
|colspan="2" style="background-color:#F0F8FF"|[[Breast cancer, HER-2 positive]]
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Dermatologic Oncology'''
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Melanoma]]
 
−
|style="background-color:#F0F8FF"|[[Basal cell and squamous cell skin cancer | Skin, basal & squamous cancer]]
 
−
|style="background-color:#F0F8FF"|[[Merkel cell carcinoma]]
 
−
|style="background-color:#F0F8FF"|
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Endocrine Oncology'''
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Germ cell tumors]]
 
−
|style="background-color:#F0F8FF"|[[Neuroendocrine tumors]]
 
−
|style="background-color:#F0F8FF"|[[Thyroid cancer]]
 
−
|style="background-color:#F0F8FF"|
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Gastrointestinal Oncology'''
 
−
|-
 
−
|style="width: 25%; background-color:#F0F8FF"|[[Anal cancer]]
 
−
|style="width: 25%; background-color:#F0F8FF"|[[Colon cancer]]
 
−
|style="width: 25%; background-color:#F0F8FF"|[[Esophageal cancer]]
 
−
|style="width: 25%; background-color:#F0F8FF"|[[Gastric cancer]]
 
−
|-
 
−
|style="width: 25%; background-color:#F0F8FF"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
 
−
|style="width: 25%; background-color:#F0F8FF"|[[Hepatobiliary cancer]]
 
−
|style="width: 25%; background-color:#F0F8FF"|[[Pancreatic cancer]]
 
−
|style="width: 25%; background-color:#F0F8FF"|[[Rectal cancer]]
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Genitourinary Oncology'''
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Bladder cancer]]
 
−
|style="background-color:#F0F8FF"|[[Germ cell tumors]]
 
−
|style="background-color:#F0F8FF"|[[Penile cancer]]
 
−
|style="background-color:#F0F8FF"|[[Prostate cancer]]
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Renal cancer|Renal cancer (RCC)]]
 
−
|style="background-color:#F0F8FF"|[[Testicular cancer]]
 
−
|style="background-color:#F0F8FF"|
 
−
|style="background-color:#F0F8FF"|
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Gynecologic Oncology'''
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Cervical cancer]]
 
−
|style="background-color:#F0F8FF"|[[Germ cell tumors]]
 
−
|style="background-color:#F0F8FF"|[[Ovarian cancer]]
 
−
|style="background-color:#F0F8FF"|[[Uterine cancer]]
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Head & Neck Oncology'''
 
−
|-
 
−
|colspan="2" style="background-color:#F0F8FF"|[[Head and neck cancer]]
 
−
|colspan="2" style="background-color:#F0F8FF"|[[Thyroid cancer]]
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Neuro-Oncology'''
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Central nervous system (CNS) cancer]]
 
−
|style="background-color:#F0F8FF"|[[Glioblastoma]]
 
−
|style="background-color:#F0F8FF"|[[CNS leukemia]]
 
−
|style="background-color:#F0F8FF"|[[CNS lymphoma]]
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Pediatric Oncology'''
 
−
|-
 
−
|colspan="4" style="background-color:#F0F8FF"|[[Neuroblastoma]]
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Sarcoma'''
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Bone cancer]]
 
−
|style="background-color:#F0F8FF"|[[Ewing's sarcoma]]
 
−
|style="background-color:#F0F8FF"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
 
−
|style="background-color:#F0F8FF"|[[Osteosarcoma]]
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Sarcoma]]
 
−
|style="background-color:#F0F8FF"|
 
−
|style="background-color:#F0F8FF"|
 
−
|style="background-color:#F0F8FF"|
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Thoracic Oncology'''
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Esophageal cancer]]
 
−
|style="background-color:#F0F8FF"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]]
 
−
|style="background-color:#F0F8FF"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]]
 
−
|style="background-color:#F0F8FF"|[[Mesothelioma]]
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[Thymoma]]
 
−
|style="background-color:#F0F8FF"|
 
−
|style="background-color:#F0F8FF"|
 
−
|style="background-color:#F0F8FF"|
 
−
|-
 
−
|colspan="4" style="background-color:#93cdff"|'''Site-agnostic'''
 
−
|-
 
−
|style="background-color:#F0F8FF"|[[MSI-H or dMMR]]
 
−
|style="background-color:#F0F8FF"|[[Unknown primary]]
 
−
|style="background-color:#F0F8FF"|
 
−
|style="background-color:#F0F8FF"|
 
−
|-
 
−
|}
 
−
<span id="malignantheme"></span>
 
−
{| class="wikitable" style="float:right; margin-left: 5px;"
 
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
−
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
−
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#FF0D00"| '''Malignant Hematology'''
 
−
|-
 
−
|colspan="4" style="background-color:#ff9e99"|'''Acute leukemias'''
 
−
|-
 
−
|style="width: 25%; background-color:#FFF0F5"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
 
−
|style="width: 25%; background-color:#FFF0F5"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
 
−
|style="width: 25%; background-color:#FFF0F5"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
 
−
|style="width: 25%; background-color:#FFF0F5"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)]]
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[CNS leukemia]]
 
−
|style="background-color:#FFF0F5"|[[Transplant conditioning regimens]]
 
−
|style="background-color:#FFF0F5"|
 
−
|style="background-color:#FFF0F5"|
 
−
|-
 
−
|colspan="4" style="background-color:#ff9e99"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]]
 
−
|style="background-color:#FFF0F5"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
 
−
|style="background-color:#FFF0F5"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
 
−
|style="background-color:#FFF0F5"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[Myelodysplastic syndrome]]
 
−
|style="background-color:#FFF0F5"|[[Myelofibrosis | Primary & secondary myelofibrosis]]
 
−
|style="background-color:#FFF0F5"|[[Polycythemia vera | Polycythemia vera (PV)]]
 
−
|style="background-color:#FFF0F5"|[[Systemic mastocytosis]]
 
−
|-
 
−
|colspan="4" style="background-color:#ff9e99"|'''Mature B-, T-, and NK-cell neoplasms'''
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
 
−
|style="background-color:#FFF0F5"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
 
−
|style="background-color:#FFF0F5"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
 
−
|style="background-color:#FFF0F5"|[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | Chronic lymphocytic leukemia (CLL/SLL)]]
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[CNS lymphoma]]
 
−
|style="background-color:#FFF0F5"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
 
−
|style="background-color:#FFF0F5"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
 
−
|style="background-color:#FFF0F5"|[[Extranodal NK/T-cell lymphoma, nasal type]]
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
 
−
|style="background-color:#FFF0F5"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
 
−
|style="background-color:#FFF0F5"|[[HIV-associated lymphoma]]
 
−
|style="background-color:#FFF0F5"|[[Hodgkin lymphoma|Hodgkin lymphoma (HL)]]
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
 
−
|style="background-color:#FFF0F5"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
 
−
|style="background-color:#FFF0F5"|[[Light-chain (AL) amyloidosis]]
 
−
|style="background-color:#FFF0F5"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
 
−
|style="background-color:#FFF0F5"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
 
−
|style="background-color:#FFF0F5"|[[Multiple myeloma|Multiple myeloma (MM)]]
 
−
|style="background-color:#FFF0F5"|[[NK/T-cell lymphoma]]
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
 
−
|style="background-color:#FFF0F5"|[[Plasma cell leukemia]]
 
−
|style="background-color:#FFF0F5"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 
−
|style="background-color:#FFF0F5"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
 
−
|-
 
−
|style="background-color:#FFF0F5"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
 
−
|style="background-color:#FFF0F5"|[[Transplant conditioning regimens]]
 
−
|style="background-color:#FFF0F5"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
 
−
|style="background-color:#FFF0F5"|
 
−
|-
 
−
|}
 
−
<span id="otherheme"></span>
 
−
{| class="wikitable" style="float:right; margin-left: 5px;"
 
−
|-
 
−
|[[#top|back to top]]
 
 
|}
 
|}
−
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
+
|2017-2019
−
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#228B22"|'''Other Hematology'''
+
| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
−
|-
+
|1a. [[#Carboplatin_.26_Paclitaxel_.28CP.29|CP]]<br>1b. [[#Cisplatin_.26_Vinorelbine_.28CVb.29|CVb]]<br>1c. [[#Cisplatin_.26_Docetaxel_.28DC.29|DC]]
−
|style="width: 25%; background-color:#F0FFF0"|[[Aplastic anemia]]
+
| style="background-color:#1a9850" |Superior EFS (co-primary endpoint)<br>Median EFS: 31.6 vs 20.8 mo<br>(HR 0.63, 97.38% CI 0.43-0.91)<br><br>Superior pCR rate (co-primary endpoint)<br>pCR rate: 24% vs 2.2%<br>(OR 13.94, 99% CI 3.49-55.75)
−
|style="width: 25%; background-color:#F0FFF0"|[[Atypical hemolytic-uremic syndrome (aHUS)]]
 
−
|style="width: 25%; background-color:#F0FFF0"|[[Autoimmune cytopenias]]
 
−
|style="width: 25%; background-color:#F0FFF0"|[[Autoimmune thrombocytopenic purpura (ITP)]]
 
−
|-
 
−
|style="background-color:#F0FFF0"|[[Castleman disease]]
 
−
|style="background-color:#F0FFF0"|[[Coagulopathies]]
 
−
|style="background-color:#F0FFF0"|[[Cold agglutinin disease]]
 
−
|style="background-color:#F0FFF0"|[[Hemophagocytic lymphohistiocytosis (HLH)]]
 
−
|-
 
−
|style="background-color:#F0FFF0"|[[Histiocytoses]]
 
−
|style="background-color:#F0FFF0"|[[Paroxysmal nocturnal hemoglobinuria (PNH)]]
 
−
|style="background-color:#F0FFF0"|[[Sickle cell anemia]]
 
−
|style="background-color:#F0FFF0"|[[Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura (TTP)]]
 
−
|-
 
−
|style="background-color:#F0FFF0"|[[Venous thromboembolism (VTE)]]
 
−
|style="background-color:#F0FFF0"|
 
−
|style="background-color:#F0FFF0"|
 
−
|style="background-color:#F0FFF0"|
 
 
|-
 
|-
 
|}
 
|}
−
 
+
''Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details.''
−
<div style="text-align:center"><big>'''[[Special:AllPages|Browse our complete index of pages]]'''</big></div>
+
<div class="toccolours" style="background-color:#fdcdac">
−
 
+
====Biomarker eligibility criteria====
−
==Additional Information==
+
*CheckMate 816: No sensitizing EGFR or ALK mutations
−
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100s of hematology/oncology drugs, and 1000s of antineoplastic regimens. Content is added by hematology & oncology providers, and undergoes [[how to contribute|continuous peer review]].
+
</div></div>
−
 
 
−
<br><inputbox>
 
−
type=create
 
−
width=70
 
−
placeholder=Type the name of the page you want to create
 
−
break=no
 
−
</inputbox>
 
−
Any information that one feels would be helpful to other oncology providers is welcome.  Visit [[how to contribute]] for more details.  Priorities of this project include:
 
−
 
 
−
#Creating a database of [[Drug index | chemotherapy agents and other medications]].
 
−
#Creating a database of chemotherapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
 
−
#[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
 
−
#Aggregating [[External links|useful links]] to existing resources by disease, such as information about prognosis, clinical calculators, staging, and patient resources.
 
−
 
 
−
Additional possibilities for this project may include:
 
−
#Creating summaries of pivotal clinical trials
 
−
#Establishing homepages for ongoing clinical trials that contain information and sites of participation
 
−
#Checklists for common clinical scenarios/diseases
 
−
#Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
 
−
 
 
−
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource.  The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access.  We believe that the familiar format of a Wiki, made popular by sites such as [http://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
 

Latest revision as of 12:58, 18 July 2024

Carboplatin & Paclitaxel (CP) & Nivolumab

CP & Nivolumab: Carboplatin, Paclitaxel, Nivolumab

Regimen variant #1, 5/175/360

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Forde et al. 2022 (CheckMate 816)
Alt text
Click to learn more!
2017-2019 Phase 3 (E-RT-esc) 1a. CP
1b. CVb
1c. DC 		Superior EFS (co-primary endpoint)
Median EFS: 31.6 vs 20.8 mo
(HR 0.63, 97.38% CI 0.43-0.91)

Superior pCR rate (co-primary endpoint)
pCR rate: 24% vs 2.2%
(OR 13.94, 99% CI 3.49-55.75)

Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details.

Biomarker eligibility criteria

  • CheckMate 816: No sensitizing EGFR or ALK mutations
Retrieved from "https://hemonc.org/w/index.php?title=Editing_test_page&oldid=89958"